Who makes SIM1803-1A?

SIM1803-1A is developed by Jiangsu Simcere Pharmaceutical Co., Ltd..

Last reviewed 2026-04-19 · How we verify

SIM1803-1A

Jiangsu Simcere Pharmaceutical Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	SIM1803-1A
Sponsor	Jiangsu Simcere Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SIM1803-1A CI brief — competitive landscape report
SIM1803-1A updates RSS · CI watch RSS
Jiangsu Simcere Pharmaceutical Co., Ltd. portfolio CI